Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

SIMPLE SUMMARY: We investigated for the first time the safety profile of COVID-19 vaccines in patients receiving new antineoplastic agents in early-stage clinical trials, including new immuno-regulatory anti-cancer investigational compounds and drug combinations. We found that about three-quarters o...

Descripción completa

Detalles Bibliográficos
Autores principales: Trillo Aliaga, Pamela, Trapani, Dario, Sandoval, José Luis, Crimini, Edoardo, Antonarelli, Gabriele, Vivanet, Grazia, Morganti, Stefania, Corti, Chiara, Tarantino, Paolo, Friedlaender, Alex, Belli, Carmen, Minchella, Ida, Locatelli, Marzia, Esposito, Angela, Criscitiello, Carmen, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616209/
https://www.ncbi.nlm.nih.gov/pubmed/34830983
http://dx.doi.org/10.3390/cancers13225829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616209/
https://www.ncbi.nlm.nih.gov/pubmed/34830983
http://dx.doi.org/10.3390/cancers13225829

Ejemplares similares